Evidence map›Paper›PMID 33509020›Full record

ArticleThyroid : official journal of the American Thyroid Association2021

Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma.

Christine Dierks, Jochen Seufert, Konrad Aumann, Juri Ruf, Claudius Klein, Selina Kiefer, Michael Rassner, Melanie Boerries, Andreas Zielke, Paul la Rosee and 12 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Thyroid : official journal of the American Thyroid Association, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 148 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
148citing papers in PubMed, 9 pooled it
22.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

148 citing papers in PubMed, 9 syntheses or guidelines pooled it, 230 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Guideline
  4. Pooled it
  5. SEOM-GETNE-TTCC Clinical guideline thyroid cancer (2023).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Guideline
  6. Pooled it
  7. Poorly differentiated thyroid carcinomas: conceptual controversy and clinical impact.Virchows Archiv : an international journal of pathology · 2024
    Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914).Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Trial
  13. Trial
  14. Trial
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Thyroid Cancer: Epidemiology, Diagnosis, and Treatment.Deutsches Arzteblatt international · 2026
    Review

88 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 8 institutions in 2 countries.

Christine DierksDepartment of Hematology and Oncology, KIM IV, Faculty of Medicine, University Halle-Wittenberg, Halle, Germany.
Jochen SeufertDivision of Endocrinology and Diabetology, Department of Medicine II, University of Freiburg, Freiburg, Germany.
Konrad AumannInstitute of Pathology, University of Freiburg, Germany.
Juri RufDepartment of Nuclear Medicine, University of Freiburg, Germany.
Claudius KleinDepartment of Hematology and Oncology, University of Freiburg, Freiburg, Germany.
Selina KieferInstitute of Pathology, University of Freiburg, Germany.
Michael RassnerDepartment of Hematology and Oncology, University of Freiburg, Freiburg, Germany.
Melanie BoerriesGerman Cancer Research Center (DKFZ), Heidelberg, Germany.
Andreas ZielkeOutcomes Research Unit, Department of Endocrine Surgery, Endocrine Center Stuttgart, Diakonie Klinikum Stuttgart, Stuttgart, Germany.
Paul la RoseeKlinikum Villingen-Schwenningen, Hämatologie/Onkologie, Villingen-Schwenningen, Germany.
Philipp Tobias MeyerDepartment of Nuclear Medicine, University of Freiburg, Germany.
Matthias KroissDivision of Endocrinology/Diabetology, Department of Internal Medicine, University Hospital Würzburg, Würzburg, Germany.
Christian WeißenbergerZentrum für Strahlentherapie, Freiburg, Germany.
Tilmann SchumacherPraxis für Nuklearmedizin, Freiburg, Germany.
Patrick MetzgerInstitute of Medical Bioinformatics and Systems Medicine and Institute of Molecular Medicine and Cell Research; Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Harald WeissEisai GmbH, Frankfurt/Main, Germany.
Constantin SmaxwilOutcomes Research Unit, Department of Endocrine Surgery, Endocrine Center Stuttgart, Diakonie Klinikum Stuttgart, Stuttgart, Germany.
Katharina LaubnerDivision of Endocrinology and Diabetology, Department of Medicine II, University of Freiburg, Freiburg, Germany.
Justus DuysterDepartment of Hematology and Oncology, University of Freiburg, Freiburg, Germany.
Nikolas von BubnoffDepartment of Hematology and Oncology, University of Freiburg, Freiburg, Germany.
Cornelius MiethingDepartment of Hematology and Oncology, University of Freiburg, Freiburg, Germany.
Oliver ThomuschDepartment of General and Visceral Surgery, University Hospital Freiburg, Freiburg, Germany.
University of Freiburg · DEDiakonie-Klinikum Stuttgart · DEEisai (Germany) · DEKlinik und Poliklinik für Nuklearmedizin · DENephrologisches Zentrum Villingen-Schwenningen · DEUniversitätsklinik für Strahlentherapie · DEUniversity Medical Center Freiburg · DEUniversity of Würzburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AgedAged, 80 and overAntibodies, Monoclonal, HumanizedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansMaleMiddle AgedPhenylurea CompoundsQuinolinesRetrospective StudiesSurvival RateThyroid Carcinoma, AnaplasticThyroid NeoplasmsTreatment OutcomeAntibodies, Monoclonal, HumanizedAntineoplastic AgentslenvatinibpembrolizumabPhenylurea CompoundsQuinolinesanaplastic thyroid cancerATClenvatinibPDTCpembrolizumabpoorly differentiated thyroid cancer

Identifiers

PMID33509020
PMCPMC8290324
OpenAlexW3124581135

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.